Drugs like Ozempic and Wegovy — known as glucagon-like peptide-1 receptor agonists, or GLP-1s — have made headlines and surged in popularity for their unique ability to help patients lose weight by reducing food cravings.

T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing weight. In report published in Nature Medicine,